Thyrocare Technologies Limited

THYROCARE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, THYROCARE.NS stands at 19.4B. In comparison, LALPATHLAB.BO has a market cap of 222B. Regarding current trading prices, THYROCARE.NS is priced at ₹366.00, while LALPATHLAB.BO trades at ₹1,329.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

THYROCARE.NS currently has a P/E ratio of 42.02, whereas LALPATHLAB.BO's P/E ratio is 41.99. In terms of profitability, THYROCARE.NS's ROE is +0.26%, compared to LALPATHLAB.BO's ROE of +0.24%. Regarding short-term risk, THYROCARE.NS is less volatile compared to LALPATHLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for THYROCARE.NS.Check LALPATHLAB.BO's competition here

THYROCARE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, THYROCARE.NS stands at 19.4B. In comparison, LALPATHLAB.NS has a market cap of 221.9B. Regarding current trading prices, THYROCARE.NS is priced at ₹366.00, while LALPATHLAB.NS trades at ₹1,328.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

THYROCARE.NS currently has a P/E ratio of 42.02, whereas LALPATHLAB.NS's P/E ratio is 42.02. In terms of profitability, THYROCARE.NS's ROE is +0.26%, compared to LALPATHLAB.NS's ROE of +0.24%. Regarding short-term risk, THYROCARE.NS is less volatile compared to LALPATHLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for THYROCARE.NS.Check LALPATHLAB.NS's competition here

THYROCARE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, THYROCARE.NS stands at 19.4B. In comparison, SAILIFE.NS has a market cap of 203.3B. Regarding current trading prices, THYROCARE.NS is priced at ₹366.00, while SAILIFE.NS trades at ₹959.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

THYROCARE.NS currently has a P/E ratio of 42.02, whereas SAILIFE.NS's P/E ratio is 60.68. In terms of profitability, THYROCARE.NS's ROE is +0.26%, compared to SAILIFE.NS's ROE of +0.15%. Regarding short-term risk, THYROCARE.NS is more volatile compared to SAILIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for THYROCARE.NS.Check SAILIFE.NS's competition here

THYROCARE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, THYROCARE.NS stands at 19.4B. In comparison, VIJAYA.NS has a market cap of 92.1B. Regarding current trading prices, THYROCARE.NS is priced at ₹366.00, while VIJAYA.NS trades at ₹897.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

THYROCARE.NS currently has a P/E ratio of 42.02, whereas VIJAYA.NS's P/E ratio is 57.84. In terms of profitability, THYROCARE.NS's ROE is +0.26%, compared to VIJAYA.NS's ROE of +0.20%. Regarding short-term risk, THYROCARE.NS is less volatile compared to VIJAYA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for THYROCARE.NS.Check VIJAYA.NS's competition here

THYROCARE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, THYROCARE.NS stands at 19.4B. In comparison, VIJAYA.BO has a market cap of 92B. Regarding current trading prices, THYROCARE.NS is priced at ₹366.00, while VIJAYA.BO trades at ₹895.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

THYROCARE.NS currently has a P/E ratio of 42.02, whereas VIJAYA.BO's P/E ratio is 57.76. In terms of profitability, THYROCARE.NS's ROE is +0.26%, compared to VIJAYA.BO's ROE of +0.20%. Regarding short-term risk, THYROCARE.NS is less volatile compared to VIJAYA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for THYROCARE.NS.Check VIJAYA.BO's competition here

THYROCARE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, THYROCARE.NS stands at 19.4B. In comparison, METROPOLIS.BO has a market cap of 87.7B. Regarding current trading prices, THYROCARE.NS is priced at ₹366.00, while METROPOLIS.BO trades at ₹422.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

THYROCARE.NS currently has a P/E ratio of 42.02, whereas METROPOLIS.BO's P/E ratio is 52.15. In terms of profitability, THYROCARE.NS's ROE is +0.26%, compared to METROPOLIS.BO's ROE of +0.13%. Regarding short-term risk, THYROCARE.NS is less volatile compared to METROPOLIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for THYROCARE.NS.Check METROPOLIS.BO's competition here

THYROCARE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, THYROCARE.NS stands at 19.4B. In comparison, METROPOLIS.NS has a market cap of 87.4B. Regarding current trading prices, THYROCARE.NS is priced at ₹366.00, while METROPOLIS.NS trades at ₹421.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

THYROCARE.NS currently has a P/E ratio of 42.02, whereas METROPOLIS.NS's P/E ratio is 52.26. In terms of profitability, THYROCARE.NS's ROE is +0.26%, compared to METROPOLIS.NS's ROE of +0.13%. Regarding short-term risk, THYROCARE.NS is less volatile compared to METROPOLIS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for THYROCARE.NS.Check METROPOLIS.NS's competition here

THYROCARE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, THYROCARE.NS stands at 19.4B. In comparison, THYROCARE.BO has a market cap of 19.4B. Regarding current trading prices, THYROCARE.NS is priced at ₹366.00, while THYROCARE.BO trades at ₹366.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

THYROCARE.NS currently has a P/E ratio of 42.02, whereas THYROCARE.BO's P/E ratio is 42.04. In terms of profitability, THYROCARE.NS's ROE is +0.26%, compared to THYROCARE.BO's ROE of +0.26%. Regarding short-term risk, THYROCARE.NS is less volatile compared to THYROCARE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for THYROCARE.NS.Check THYROCARE.BO's competition here

THYROCARE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, THYROCARE.NS stands at 19.4B. In comparison, VIMTALABS.BO has a market cap of 18.3B. Regarding current trading prices, THYROCARE.NS is priced at ₹366.00, while VIMTALABS.BO trades at ₹409.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

THYROCARE.NS currently has a P/E ratio of 42.02, whereas VIMTALABS.BO's P/E ratio is 24.65. In terms of profitability, THYROCARE.NS's ROE is +0.26%, compared to VIMTALABS.BO's ROE of +0.20%. Regarding short-term risk, THYROCARE.NS is less volatile compared to VIMTALABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for THYROCARE.NS.Check VIMTALABS.BO's competition here

THYROCARE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, THYROCARE.NS stands at 19.4B. In comparison, VIMTALABS.NS has a market cap of 18.3B. Regarding current trading prices, THYROCARE.NS is priced at ₹366.00, while VIMTALABS.NS trades at ₹408.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

THYROCARE.NS currently has a P/E ratio of 42.02, whereas VIMTALABS.NS's P/E ratio is 24.58. In terms of profitability, THYROCARE.NS's ROE is +0.26%, compared to VIMTALABS.NS's ROE of +0.20%. Regarding short-term risk, THYROCARE.NS is less volatile compared to VIMTALABS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for THYROCARE.NS.Check VIMTALABS.NS's competition here

THYROCARE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, THYROCARE.NS stands at 19.4B. In comparison, KRSNAA.NS has a market cap of 17.9B. Regarding current trading prices, THYROCARE.NS is priced at ₹366.00, while KRSNAA.NS trades at ₹550.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

THYROCARE.NS currently has a P/E ratio of 42.02, whereas KRSNAA.NS's P/E ratio is 22.49. In terms of profitability, THYROCARE.NS's ROE is +0.26%, compared to KRSNAA.NS's ROE of +0.09%. Regarding short-term risk, THYROCARE.NS is more volatile compared to KRSNAA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for THYROCARE.NS.Check KRSNAA.NS's competition here

THYROCARE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, THYROCARE.NS stands at 19.4B. In comparison, KRSNAA.BO has a market cap of 17.8B. Regarding current trading prices, THYROCARE.NS is priced at ₹366.00, while KRSNAA.BO trades at ₹548.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

THYROCARE.NS currently has a P/E ratio of 42.02, whereas KRSNAA.BO's P/E ratio is 22.39. In terms of profitability, THYROCARE.NS's ROE is +0.26%, compared to KRSNAA.BO's ROE of +0.09%. Regarding short-term risk, THYROCARE.NS is less volatile compared to KRSNAA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for THYROCARE.NS.Check KRSNAA.BO's competition here

THYROCARE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, THYROCARE.NS stands at 19.4B. In comparison, SURAKSHA.NS has a market cap of 12.8B. Regarding current trading prices, THYROCARE.NS is priced at ₹366.00, while SURAKSHA.NS trades at ₹244.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

THYROCARE.NS currently has a P/E ratio of 42.02, whereas SURAKSHA.NS's P/E ratio is 39.20. In terms of profitability, THYROCARE.NS's ROE is +0.26%, compared to SURAKSHA.NS's ROE of +0.16%. Regarding short-term risk, THYROCARE.NS is less volatile compared to SURAKSHA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for THYROCARE.NS.Check SURAKSHA.NS's competition here

THYROCARE.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, THYROCARE.NS stands at 19.4B. In comparison, SURAKSHA.BO has a market cap of 12.7B. Regarding current trading prices, THYROCARE.NS is priced at ₹366.00, while SURAKSHA.BO trades at ₹244.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

THYROCARE.NS currently has a P/E ratio of 42.02, whereas SURAKSHA.BO's P/E ratio is 39.12. In terms of profitability, THYROCARE.NS's ROE is +0.26%, compared to SURAKSHA.BO's ROE of +0.16%. Regarding short-term risk, THYROCARE.NS is more volatile compared to SURAKSHA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for THYROCARE.NS.Check SURAKSHA.BO's competition here